Revolution Medicines, Inc. (RVMD)
Every FINRA and SEC series the site collects for Revolution Medicines, Inc.: short interest with days to cover, daily short sale volume, fails to deliver and Form 4 insider trades. Listed on Nasdaq, classified by the SEC as biological products, (no diagnostic substances).
9.7M
Short interest
settlement 2026-08-14
6.4
Days to cover
-15.7% vs prior
58.8%
Short share of volume
2026-09-11
1
Fails to deliver
settlement 2026-07-30
-$45.0M
Insider flow, 90 days
0 buys, 35 sells
As of 2026-09-11.
Short interest
FINRA, twice a month; the last 12 months shown, all 48 settlements in the JSONAs of 14 August 2026, short interest in RVMD is 9,716,949 shares, down 4,285,829 shares over the last month. Over the last 48 readings it ranged from 9,716,949 shares (14 August 2026) to 19,363,548 shares (15 October 2025). The latest reading sits at the bottom of that range. At the reported average volume of 1.5M shares a day that is 6.4 days to cover, elevated.
Embed this chartfree, with the attribution line it carries
<iframe src="https://xoomar.com/embed/stocks/rvmd" width="100%" height="440" style="border:0;max-width:100%" loading="lazy" title="XOOMAR chart"></iframe>
| Settlement | Shares short | Change | Avg daily volume | Days to cover |
|---|---|---|---|---|
| 2026-08-14 | 9,716,949 | -15.7% | 1,528,603 | 6.36 |
| 2026-07-31 | 11,519,784 | -17.7% | 1,834,387 | 6.28 |
| 2026-07-15 | 14,002,778 | +8.7% | 2,060,932 | 6.79 |
| 2026-06-30 | 12,882,513 | +4.9% | 4,308,352 | 2.99 |
| 2026-06-15 | 12,282,512 | +6.0% | 2,850,843 | 4.31 |
| 2026-05-29 | 11,588,154 | +4.6% | 2,750,932 | 4.21 |
| 2026-05-15 | 11,075,199 | -13.5% | 2,349,181 | 4.71 |
| 2026-04-30 | 12,799,582 | -4.4% | 3,907,552 | 3.28 |
| 2026-04-15 | 13,387,469 | -13.1% | 4,402,996 | 3.04 |
| 2026-03-31 | 15,409,530 | +6.6% | 1,943,343 | 7.93 |
| 2026-03-13 | 14,457,743 | +2.4% | 1,860,881 | 7.77 |
| 2026-02-27 | 14,113,308 | +3.4% | 2,629,824 | 5.37 |
| 2026-02-13 | 13,655,708 | +4.5% | 1,980,171 | 6.90 |
| 2026-01-30 | 13,072,474 | -8.0% | 3,980,203 | 3.28 |
| 2026-01-15 | 14,216,021 | -7.2% | 7,051,184 | 2.02 |
| 2025-12-31 | 15,314,358 | +1.6% | 2,347,443 | 6.52 |
| 2025-12-15 | 15,070,669 | -10.3% | 2,215,904 | 6.80 |
| 2025-11-28 | 16,792,419 | -4.0% | 2,051,630 | 8.18 |
| 2025-11-14 | 17,485,484 | -3.0% | 2,723,493 | 6.42 |
| 2025-10-31 | 18,022,242 | -6.9% | 2,269,044 | 7.94 |
| 2025-10-15 | 19,363,548 | +7.8% | 1,967,812 | 9.84 |
| 2025-09-30 | 17,968,076 | -0.5% | 2,185,977 | 8.22 |
| 2025-09-15 | 18,053,357 | +9.2% | 2,252,642 | 8.01 |
| 2025-08-29 | 16,527,230 | +8.9% | 1,831,660 | 9.02 |
Daily short volume
FINRA Reg SHO, last 60 sessions. JSONAs of 11 September 2026, the short share of RVMD volume is 58.8%, down 3.0 points over the last five sessions. Over the last 52 readings it ranged from 29.0% (6 July 2026) to 69.0% (27 August 2026). The latest reading is 2.6 points above the 30-session average of 56.2%, on 577K shares reported.
| Date | Short volume | Total volume | Short share | Exempt |
|---|---|---|---|---|
| 2026-09-11 | 339K | 577K | 58.8% | 3,527 |
| 2026-09-10 | 216K | 322K | 67.2% | 2,448 |
| 2026-09-09 | 240K | 384K | 62.5% | 13,708 |
| 2026-09-08 | 322K | 880K | 36.6% | 13,044 |
| 2026-09-04 | 247K | 363K | 68.1% | 550 |
| 2026-09-03 | 302K | 488K | 61.8% | 13,796 |
| 2026-09-02 | 372K | 608K | 61.1% | 7,485 |
| 2026-09-01 | 477K | 755K | 63.2% | 2,028 |
| 2026-08-31 | 426K | 640K | 66.5% | 28,377 |
| 2026-08-28 | 515K | 996K | 51.7% | 13,826 |
| 2026-08-27 | 1.2M | 1.7M | 69.0% | 10,670 |
| 2026-08-26 | 1.0M | 1.8M | 56.6% | 20,377 |
| 2026-08-25 | 234K | 452K | 51.8% | 7,626 |
| 2026-08-24 | 266K | 592K | 44.9% | 20,498 |
| 2026-08-21 | 327K | 577K | 56.8% | 28,811 |
| 2026-08-20 | 227K | 531K | 42.7% | 753 |
| 2026-08-19 | 288K | 484K | 59.5% | 5,073 |
| 2026-08-18 | 479K | 916K | 52.3% | 3,917 |
| 2026-08-17 | 767K | 1.1M | 68.8% | 11,624 |
| 2026-08-14 | 197K | 330K | 59.5% | 677 |
| 2026-08-13 | 231K | 336K | 68.8% | 2,354 |
| 2026-08-12 | 187K | 550K | 34.1% | 5,830 |
| 2026-08-11 | 358K | 744K | 48.1% | 19,257 |
| 2026-08-10 | 287K | 789K | 36.4% | 13,435 |
| 2026-08-07 | 312K | 744K | 41.9% | 16 |
| 2026-08-06 | 407K | 630K | 64.5% | 270 |
| 2026-08-05 | 463K | 794K | 58.3% | 1,784 |
| 2026-08-04 | 474K | 794K | 59.7% | 59,378 |
| 2026-08-03 | 351K | 599K | 58.6% | 1,506 |
| 2026-07-31 | 366K | 645K | 56.8% | 1,092 |
Fails to deliver
SEC, by settlement date. JSONAs of 30 July 2026, the fails-to-deliver balance in RVMD is 1 share, down 99 shares over the last settlement date. Over the last 52 readings it ranged from 1 share (6 November 2025) to 252,389 shares (25 March 2026). The latest reading sits at the bottom of that range.
| Settlement | Shares failed | Price | Value |
|---|---|---|---|
| 2026-07-30 | 1 | $180.92 | $181 |
| 2026-07-24 | 100 | $188.75 | $19K |
| 2026-07-23 | 100 | $183.03 | $18K |
| 2026-07-22 | 100 | $183.29 | $18K |
| 2026-07-20 | 12 | $186.16 | $2K |
| 2026-07-17 | 108 | $179.18 | $19K |
| 2026-07-06 | 778 | $189.24 | $147K |
| 2026-07-02 | 8,851 | $187.51 | $1.7M |
| 2026-06-29 | 167,291 | $182.08 | $30.5M |
| 2026-06-24 | 4 | $169.51 | $678 |
| 2026-06-22 | 16,264 | $162.99 | $2.7M |
| 2026-06-18 | 36 | $157.77 | $6K |
| 2026-06-17 | 31 | $156.58 | $5K |
| 2026-06-15 | 616 | $153.87 | $95K |
| 2026-06-12 | 3 | $149.23 | $448 |
| 2026-06-10 | 33 | $149.55 | $5K |
| 2026-06-05 | 995 | $155.69 | $155K |
| 2026-06-04 | 89 | $155.99 | $14K |
| 2026-04-23 | 496 | $141.50 | $70K |
| 2026-04-21 | 1 | $146.23 | $146 |
| 2026-04-20 | 2,345 | $148.63 | $349K |
| 2026-04-16 | 10 | $152.54 | $2K |
| 2026-04-15 | 3,375 | $147.01 | $496K |
| 2026-04-02 | 1 | $98.64 | $99 |
| 2026-03-25 | 252,389 | $95.52 | $24.1M |
| 2026-03-20 | 1,324 | $99.29 | $131K |
| 2026-03-12 | 48,958 | $99.59 | $4.9M |
| 2026-03-05 | 1,937 | $101.19 | $196K |
| 2026-02-23 | 12 | $101.83 | $1K |
| 2026-02-20 | 35,325 | $102.74 | $3.6M |
Insider trades
SEC Form 4, newest first, 50 of 100 shown. JSONInsiders at RVMD reported 35 open-market sells worth $45.0M in the last 90 days and no open-market buys. Sells alone are a weak signal; insiders sell for tax, diversification and estate reasons all the time. Latest filing: Kim Lorence H. on 2026-08-31.
| Date | Insider | Title | Type | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|---|
| 2026-08-31 | Kim Lorence H. | n/a | Sell | 625 | $206.15 | $129K | 17K |
| 2026-08-31 | Kim Lorence H. | n/a | Sell | 2K | $205.19 | $437K | 18K |
| 2026-08-31 | Kim Lorence H. | n/a | Sell | 7K | $204.35 | $1.5M | 20K |
| 2026-08-31 | Kim Lorence H. | n/a | Sell | 26K | $203.55 | $5.3M | 27K |
| 2026-08-31 | Kim Lorence H. | n/a | Sell | 13K | $202.48 | $2.6M | 53K |
| 2026-08-31 | Kim Lorence H. | n/a | Sell | 7K | $201.47 | $1.3M | 66K |
| 2026-08-31 | Kim Lorence H. | n/a | Sell | 300 | $200.56 | $60K | 73K |
| 2026-08-21 | GOLDSMITH MARK A | See Remarks | Sell | 229 | $211.46 | $48K | 62K |
| 2026-08-21 | GOLDSMITH MARK A | See Remarks | Sell | 126 | $210.40 | $27K | 62K |
| 2026-08-21 | GOLDSMITH MARK A | See Remarks | Sell | 1K | $209.27 | $294K | 62K |
| 2026-08-21 | GOLDSMITH MARK A | See Remarks | Sell | 937 | $208.36 | $195K | 63K |
| 2026-08-21 | GOLDSMITH MARK A | See Remarks | Sell | 177 | $207.25 | $37K | 64K |
| 2026-08-21 | GOLDSMITH MARK A | See Remarks | Sell | 127 | $212.06 | $27K | 61K |
| 2026-08-21 | GOLDSMITH MARK A | See Remarks | Sell | 245 | $211.47 | $52K | 62K |
| 2026-08-21 | GOLDSMITH MARK A | See Remarks | Sell | 136 | $210.40 | $29K | 62K |
| 2026-08-21 | GOLDSMITH MARK A | See Remarks | Sell | 1K | $209.28 | $283K | 62K |
| 2026-08-21 | GOLDSMITH MARK A | See Remarks | Sell | 951 | $208.36 | $198K | 63K |
| 2026-08-21 | GOLDSMITH MARK A | See Remarks | Sell | 190 | $207.25 | $39K | 64K |
| 2026-08-21 | GOLDSMITH MARK A | See Remarks | Sell | 4K | $212.08 | $768K | 267K |
| 2026-08-21 | GOLDSMITH MARK A | See Remarks | Sell | 7K | $211.33 | $1.4M | 271K |
| 2026-08-21 | GOLDSMITH MARK A | See Remarks | Sell | 4K | $210.25 | $802K | 278K |
| 2026-08-21 | GOLDSMITH MARK A | See Remarks | Sell | 36K | $209.26 | $7.5M | 281K |
| 2026-08-21 | GOLDSMITH MARK A | See Remarks | Sell | 25K | $208.37 | $5.2M | 317K |
| 2026-08-21 | GOLDSMITH MARK A | See Remarks | Sell | 5K | $207.23 | $1.1M | 342K |
| 2026-08-21 | GOLDSMITH MARK A | See Remarks | Option exercise | 80K | $4.73 | $378K | 347K |
| 2026-08-21 | Cislini Jeff | General Counsel | Sell | 3K | $212.06 | $703K | 56K |
| 2026-08-21 | Cislini Jeff | General Counsel | Sell | 5K | $211.34 | $951K | 59K |
| 2026-08-21 | Cislini Jeff | General Counsel | Sell | 3K | $210.26 | $534K | 64K |
| 2026-08-21 | Cislini Jeff | General Counsel | Sell | 26K | $209.25 | $5.4M | 66K |
| 2026-08-21 | Cislini Jeff | General Counsel | Sell | 17K | $208.37 | $3.6M | 92K |
| 2026-08-21 | Cislini Jeff | General Counsel | Sell | 3K | $207.24 | $705K | 109K |
| 2026-08-21 | Cislini Jeff | General Counsel | Option exercise | 27K | $21.61 | $575K | 113K |
| 2026-08-21 | Cislini Jeff | General Counsel | Option exercise | 30K | $18.56 | $551K | 86K |
| 2026-06-24 | Anders Jack | Chief Financial Officer | Sell | 300 | $170.32 | $51K | 123K |
| 2026-06-24 | Anders Jack | Chief Financial Officer | Sell | 6K | $169.24 | $956K | 124K |
| 2026-06-24 | Anders Jack | Chief Financial Officer | Sell | 9K | $168.20 | $1.6M | 129K |
| 2026-06-24 | Anders Jack | Chief Financial Officer | Sell | 5K | $167.34 | $762K | 139K |
| 2026-06-24 | Anders Jack | Chief Financial Officer | Option exercise | 20K | $18.56 | $371K | 143K |
| 2026-06-18 | Borisy Alexis | n/a | Grant | 1K | $0.00 | $0 | 2.3M |
| 2026-06-18 | Borellini Flavia | n/a | Grant | 1K | $0.00 | $0 | 26K |
| 2026-06-18 | ANDERSON ELIZABETH M | n/a | Grant | 1K | $0.00 | $0 | 9K |
| 2026-06-16 | Anders Jack | Chief Financial Officer | Sell | 3K | $156.12 | $425K | 123K |
| 2026-05-26 | Mancini Anthony | See Remarks | Sell | 421 | $154.82 | $65K | 54K |
| 2026-05-26 | Mancini Anthony | See Remarks | Sell | 2K | $154.06 | $308K | 55K |
| 2026-05-26 | Mancini Anthony | See Remarks | Sell | 700 | $153.30 | $107K | 57K |
| 2026-05-26 | Mancini Anthony | See Remarks | Option exercise | 3K | $33.62 | $105K | 58K |
| 2026-04-27 | Mancini Anthony | See Remarks | Sell | 400 | $134.34 | $54K | 54K |
| 2026-04-27 | Mancini Anthony | See Remarks | Sell | 1K | $132.88 | $139K | 55K |
| 2026-04-27 | Mancini Anthony | See Remarks | Sell | 2K | $131.66 | $220K | 56K |
| 2026-04-27 | Mancini Anthony | See Remarks | Option exercise | 3K | $33.62 | $105K | 58K |
Form 4 filings are due within two business days of the trade. Insiders sell for many reasons that say nothing about the company; open-market buys are the rarer, stronger signal.
Planned sales (Form 144)
Newest first. JSON6 Form 144 notices on file for RVMD worth $56.3M at the prices reported; 6 in the last 90 days worth $56.3M. Latest: STEPHEN KELSEY filed on 2026-09-11 to sell 92,531 shares ($18.8M) from 2026-09-11.
| Filed | Seller | Shares | Market value | Of outstanding | Sale from | Broker |
|---|---|---|---|---|---|---|
| 2026-09-11 | STEPHEN KELSEYOfficer | 93K | $18.8M | 0.043% | 2026-09-11 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2026-09-10 | ANTHONY MANCINIOfficer | 15K | $3.2M | 0.007% | 2026-09-10 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2026-08-21 | THE JONATHAN GOLDSMITH REVOCABLE TRUSTDirector, Officer | 3K | $635K | 0.001% | 2026-08-21 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2026-08-21 | THE REBECCA GOLDSMITH REVOCABLE TRUSTDirector, Officer | 3K | $635K | 0.001% | 2026-08-21 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2026-08-21 | MARK A GOLDSMITHDirector, Officer | 80K | $16.9M | 0.037% | 2026-08-21 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2026-08-21 | JEFFREY TODD CISLINIOfficer | 76K | $16.1M | 0.035% | 2026-08-21 | Morgan Stanley Smith Barney LLC Executive Financial Services |
Large holders (13D and 13G)
One row per reporting person, newest filing first. JSON35 holders above 5% have filed on RVMD, all on Schedule 13G (passive). The largest reported stake is Dreyfuss, Philip D. at 6.4% of the class (13,564,149 shares), filed 2026-08-13 for an event on 2026-06-30.
| Filed | Form | Holder | Shares | Of class | Event |
|---|---|---|---|---|---|
| 2026-08-14 | 13G | Baker Bros. Advisors (GP) LLCparent holding company, other entity | 11.4M | 5.3% | 2026-06-30 |
| 2026-08-14 | 13G | Baker Bros. Advisors LPinvestment adviser, partnership | 11.4M | 5.3% | 2026-06-30 |
| 2026-08-14 | 13G | Felix J. Bakerparent holding company, individual | 11.4M | 5.3% | 2026-06-30 |
| 2026-08-14 | 13G | Julian C. Bakerparent holding company, individual | 11.4M | 5.3% | 2026-06-30 |
| 2026-08-13 | 13G/Ano. 4 | Dreyfuss, Philip D.parent holding company, individual | 13.6M | 6.4% | 2026-06-30 |
| 2026-08-13 | 13G/Ano. 4 | Farallon Capital Management, L.L.C.investment adviser, other entity | 13.6M | 6.4% | 2026-06-30 |
| 2026-08-13 | 13G/Ano. 4 | Dapice Joshua J.parent holding company, individual | 13.6M | 6.4% | 2026-06-30 |
| 2026-08-13 | 13G/Ano. 4 | Dunn Hannah E.parent holding company, individual | 13.6M | 6.4% | 2026-06-30 |
| 2026-08-13 | 13G/Ano. 4 | Gehani, Varun N.parent holding company, individual | 13.6M | 6.4% | 2026-06-30 |
| 2026-08-13 | 13G/Ano. 4 | Giauque, Nicolasparent holding company, individual | 13.6M | 6.4% | 2026-06-30 |
| 2026-08-13 | 13G/Ano. 4 | Husen, Avner A.parent holding company, individual | 13.6M | 6.4% | 2026-06-30 |
| 2026-08-13 | 13G/Ano. 4 | Kim, David T.parent holding company, individual | 13.6M | 6.4% | 2026-06-30 |
| 2026-08-13 | 13G/Ano. 4 | Linn, Michael G.parent holding company, individual | 13.6M | 6.4% | 2026-06-30 |
| 2026-08-13 | 13G/Ano. 4 | Luo Patrick (Cheng)parent holding company, individual | 13.6M | 6.4% | 2026-06-30 |
| 2026-08-13 | 13G/Ano. 4 | Roberts, Jr., Thomas G.parent holding company, individual | 13.6M | 6.4% | 2026-06-30 |
| 2026-08-13 | 13G/Ano. 4 | Saito Edric C.parent holding company, individual | 13.6M | 6.4% | 2026-06-30 |
| 2026-08-13 | 13G/Ano. 4 | Short Daniel S.parent holding company, individual | 13.6M | 6.4% | 2026-06-30 |
| 2026-08-13 | 13G/Ano. 4 | Spokes, Andrew J. M.parent holding company, individual | 13.6M | 6.4% | 2026-06-30 |
| 2026-08-13 | 13G/Ano. 4 | Warren, John R.parent holding company, individual | 13.6M | 6.4% | 2026-06-30 |
| 2026-08-13 | 13G/Ano. 4 | Wehrly, Mark C.parent holding company, individual | 13.6M | 6.4% | 2026-06-30 |
| 2026-08-13 | 13G | JANUS HENDERSON GROUP Ltd.parent holding company | 10.7M | 5.1% | 2026-06-30 |
| 2026-08-13 | 13G/Ano. 4 | Farallon Capital Institutional Partners III, L.P.partnership | 0 | 0.0% | 2026-06-30 |
| 2026-08-13 | 13G/Ano. 4 | Four Crossings Institutional Partners V, L.P.partnership | 0 | 0.0% | 2026-06-30 |
| 2026-08-13 | 13G/Ano. 4 | Farallon Capital Offshore Investors II, L.P.partnership | 0 | 0.0% | 2026-06-30 |
| 2026-08-13 | 13G/Ano. 4 | Farallon Capital (AM) Investors, L.P.partnership | 0 | 0.0% | 2026-06-30 |
| 2026-08-13 | 13G/Ano. 4 | Farallon Capital F5 Master I, L.P.partnership | 0 | 0.0% | 2026-06-30 |
| 2026-08-13 | 13G/Ano. 4 | Farallon Healthcare Partners Master, L.P.partnership | 0 | 0.0% | 2026-06-30 |
| 2026-08-13 | 13G/Ano. 4 | Farallon Partners, L.L.C.other entity | 0 | 0.0% | 2026-06-30 |
| 2026-08-13 | 13G/Ano. 4 | Farallon Institutional (GP) V, L.L.C.other entity | 0 | 0.0% | 2026-06-30 |
| 2026-08-13 | 13G/Ano. 4 | Farallon F5 (GP), L.L.C.other entity | 0 | 0.0% | 2026-06-30 |
| 2026-08-13 | 13G/Ano. 4 | Farallon Healthcare Partners (GP), L.L.C.other entity | 0 | 0.0% | 2026-06-30 |
| 2026-08-13 | 13G/Ano. 4 | Farallon Capital Partners, L.P.partnership | 0 | 0.0% | 2026-06-30 |
| 2026-08-13 | 13G/Ano. 4 | Farallon Capital Institutional Partners II, L.P.partnership | 0 | 0.0% | 2026-06-30 |
| 2026-08-13 | 13G/Ano. 4 | Farallon Capital Institutional Partners, L.P.partnership | 0 | 0.0% | 2026-06-30 |
| 2026-07-29 | 13G | BlackRock, Inc.parent holding company | 12.2M | 5.7% | 2026-06-30 |
13F holders
Tracked managers holding RVMD at their latest 13F. JSON11 of the 30 tracked managers held RVMD at their latest 13F, $833.8M in total at quarter-end prices. AQR Capital Management is the largest at $242.6M (0.1% of its portfolio) as of 2026-06-30. Over the prior quarter 5 added shares and 5 cut.
| Fund | Quarter | Shares | Value | Of portfolio | Change in shares |
|---|---|---|---|---|---|
| AQR Capital Management | 2026-06-30 | 1.3M | $242.6M | 0.08% | +1.2M |
| Citadel Advisors | 2026-06-30 | 1.2M | $227.1M | 0.03% | +208K |
| Two Sigma Investments | 2026-06-30 | 738K | $138.2M | 0.10% | -821K |
| Duquesne Family Office | 2026-06-30 | 400K | $74.8M | 1.44% | +84K |
| Millennium Management | 2026-06-30 | 263K | $49.3M | 0.02% | -4.8M |
| Fisher Asset Management | 2026-06-30 | 208K | $38.9M | 0.01% | -8K |
| D. E. Shaw & Co. | 2026-06-30 | 138K | $25.8M | 0.01% | -1.4M |
| Point72 Asset Management | 2026-06-30 | 81K | $15.1M | 0.02% | +78K |
| D. E. Shaw & Co. | 2026-06-30 | 1.6M | $14.9M | 0.01% | 0 |
| Millennium Management | 2026-06-30 | 5.1M | $6.4M | 0.00% | +5.0M |
| Millennium Management | 2026-06-30 | 87K | $814K | 0.00% | -176K |
Only the 30 tracked managers on the funds hub; a 13F reports long positions in US listed stock at quarter end, 45 days late, and says nothing about shorts or positions sold since.
Financials
SEC XBRL, as filed. JSONIn FY 2025 it generated -$897.7M of operating cash flow.
- Cash
- $815.4M
- Equity
- $2.61B
- Total assets
- $4.32B
- Shares outstanding
- 214,336,418
Quarterly, last 8 quarters
| Quarter | Period end | Revenue | Net income | Margin | Diluted EPS |
|---|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | n/a | -$644.4M | n/a | -3.06 |
| Q1 2026 | 2026-03-31 | n/a | -$453.8M | n/a | -2.29 |
| Q4 2025derived | 2025-12-31 | n/a | n/a | n/a | n/a |
| Q3 2025 | 2025-09-30 | n/a | -$305.2M | n/a | -1.61 |
| Q2 2025 | 2025-06-30 | n/a | -$247.8M | n/a | -1.31 |
| Q1 2025 | 2025-03-31 | n/a | -$213.4M | n/a | -1.13 |
| Q4 2024derived | 2024-12-31 | $0 | n/a | n/a | n/a |
| Q3 2024 | 2024-09-30 | $0 | -$156.3M | n/a | -0.94 |
Fiscal years, with buybacks and dividends
| Fiscal year | Ends | Revenue | Net income | Operating cash flow | Capex | Buybacks | Dividends |
|---|---|---|---|---|---|---|---|
| FY 2025 | 2025-12-31 | $0 | n/a | -$897.7M | $16.0M | n/a | n/a |
| FY 2024 | 2024-12-31 | $0 | n/a | -$557.4M | $10.3M | n/a | n/a |
| FY 2023 | 2023-12-31 | $11.6M | n/a | -$350.6M | $7.7M | n/a | n/a |
| FY 2022 | 2022-12-31 | $35.4M | n/a | -$224.4M | $10.8M | n/a | n/a |
| FY 2021 | 2021-12-31 | $29.4M | n/a | -$147.2M | $6.5M | n/a | n/a |
Quarters are the three-month figures the company reports; a fourth quarter marked derived is the fiscal year less the three reported quarters, since companies report it only inside the 10-K. Fiscal years are the annual figures. Buybacks are cash paid to repurchase common stock in the year (XBRL PaymentsForRepurchaseOfCommonStock), not authorizations. Balance sheet lines are as of 2026-06-30; shares outstanding as of 2026-07-31 from the cover page.
What this page is
Revolution Medicines, Inc. in the regulatory record
Regulators publish company data in separate files that never sit next to each other: FINRA's twice-monthly short interest, its daily short sale volume, the SEC's fails-to-deliver counts, and each insider's Form 4. A company page pulls every series the site collects for one ticker onto one URL, keyed by the SEC's own ticker list, so the short position, the daily flow, the settlement fails and what insiders are doing can be read together.
Each section has its own history table, a summary sentence built from the rows (last value, change, range with dates) and its own JSON and CSV links. Nothing on the page is written by a model; the sentences change only when the data does. A page exists only for companies with data in at least two series, and every section says when its source last updated.
This page follows Revolution Medicines, Inc. (RVMD), SEC CIK 1628171, listed on Nasdaq, classified by the SEC as biological products, (no diagnostic substances). The cross-market tables live on the short interest and insider transactions hubs.
Source and method
- Short interest
- FINRA consolidated short interestTwice a month, about eight business days after settlement. Latest 2026-08-14.JSON and CSV
- Daily short volume
- FINRA Reg SHO daily filesEvery trading day, loaded the following morning. Latest 2026-09-11.JSON and CSV
- Fails to deliver
- SEC fails-to-deliver dataTwice a month, a few weeks after the half month ends. Latest 2026-07-30.JSON and CSV
- Planned sales
- SEC EDGAR Form 144EDGAR read every 30 minutes; a notice is filed on or before the sell order. Latest 2026-09-11.JSON and CSV
- Large holders
- SEC EDGAR Schedule 13D and 13GEDGAR read every 30 minutes; 13D within five business days of crossing 5%, 13G on the passive schedule. Latest 2026-08-14.JSON and CSV
- 13F holders
- SEC EDGAR Form 13F-HRQuarterly, filed within 45 days of quarter end; 30 tracked managers. Latest 2026-06-30.JSON and CSV
- Financials
- SEC XBRL company factsRefreshed weekly from the SEC's structured data; values are as filed in the 10-Q and 10-K. Latest 2026-06-30.JSON and CSV
- Insider trades
- SEC EDGAR Form 4EDGAR read every 30 minutes; filings are due two business days after the trade. Latest 2026-08-31.JSON and CSV
- Company record
- EDGAR filing index for CIK 1628171Ticker, name and exchange from the SEC's company list, refreshed weekly.
- Rate limits
- 30 requests a minute without a key, 120 a minute with a key from a free account.
Data checks. Every dataset is checked against its source once a day. This dataset passed the last run, 13 Sep 05:40 UTC.
How to read it
- Read the position against the flow: rising short interest with a high daily short share is new shorting; rising short interest with a normal short share is old shorts holding on.
- Insider buys next to a crowded short are the combination that has historically preceded squeezes; insider sells next to a crowded short are common and mean little.
- Fails to deliver matter relative to the float, not in absolute shares; a million failed shares in a mega cap is noise.
Analysis of what the data shows, not advice. XOOMAR does not recommend buying, selling or holding anything.
Other companies the SEC classifies as biological products, (no diagnostic substances)
- KYMRKymera Therapeutics, Inc.
- ADPTAdaptive Biotechnologies Corp
- TWSTTwist Bioscience Corp
- HALOHALOZYME THERAPEUTICS, INC.
- KRYSKrystal Biotech, Inc.
- NBIXNEUROCRINE BIOSCIENCES INC
- AMGNAMGEN INC
- MAZEMaze Therapeutics, Inc.
- GILDGILEAD SCIENCES, INC.
- RXRXRECURSION PHARMACEUTICALS, INC.
- APGEApogee Therapeutics, Inc.
- FENCFENNEC PHARMACEUTICALS INC.
- PCVXVaxcyte, Inc.
- BIIBBIOGEN INC.
- VORVor Biopharma Inc.
- EXELEXELIXIS, INC.
- SRRKScholar Rock Holding Corp
- ADMAADMA BIOLOGICS, INC.
- VCELVericel Corp
- TECHBIO-TECHNE Corp
- ARTVArtiva Biotherapeutics, Inc.
- BCRXBIOCRYST PHARMACEUTICALS INC
- VIRVir Biotechnology, Inc.
- IOVAIOVANCE BIOTHERAPEUTICS, INC.
Datasets
Frequently Asked Questions
How much of RVMD is sold short?
What is RVMD's daily short volume?
Does RVMD have fails to deliver?
Are RVMD insiders buying or selling?
Have RVMD insiders filed to sell?
Who owns more than 5% of RVMD?
What did RVMD report last quarter?
Which funds hold RVMD?
Data on this page is provided for informational purposes only and is not financial advice. See our editorial policy.